Healios KK 4593.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 4593.T. It has been listed since 16 June 2015. In the fiscal year to 31 December 2025, it reported revenue of ¥104.0m and a net loss of ¥2.22bn. At that date it held total assets of ¥17.05bn and shareholders' equity of ¥4.89bn.

Healios KK engages in the research, development, and sale of cellular and regenerative medicine. The company is headquartered in Chiyoda-Ku, Tokyo-To. The company went IPO on 2015-06-16. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The firm has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Tadahisa KagimotoPresident, Chief Executive Officer, Representative Executive Officer, Director, since 2012
• Mr. Richard KincaidChief Financial Officer, Executive Officer, President of Subsidiary, Director, since 2018
• Mr. Hironobu KimuraExecutive Officer
• Mr. Glenn GormleyIndependent Director
• Mr. Seigo KashiiIndependent Director
• Ms. Yuko YogoIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.